300
Participants
Start Date
June 24, 2024
Primary Completion Date
April 21, 2026
Study Completion Date
April 21, 2026
Cagrilintide
Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide
Participants will receive once-weekly semaglutide subcutaneously.
Placebo
Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Washington Cntr Weight Mgmt, Arlington
Wendisch/Dahl Hamburg, Hamburg
Accellacare, Wilmington
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1, Toulouse
Clinical Trial Res Assoc,Inc, Plantation
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1, Saint-Herblain
InnoDiab Forschung GmbH, Essen
Midwest Inst For Clin Res, Indianapolis
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose, Münster
Forschungszentrum Ruhr KliFoCenter GmbH, Dr. med. Kahrmann, Witten
Hospices Civils de Lyon-Hopital Lyon Sud-1, Pierre-Bénite
Velocity Clinical Res-Dallas, Dallas
Aurora FDRC Inc., Costa Mesa
Capital Clin Res Ctr,LLC, Olympia
Ocean West Research Clinic, Surrey
Nova Scotia Health Authority, Halifax
Wharton Med Clin Trials, Hamilton
AmBeNet GmbH, Leipzig
The Health Centre, Bradford-on-Avon
Southmead Hospital, Bristol
Addenbrooke's Hospital_Cambridge, Cambridge
WISDEM Centre, Coventry
The Staploe Medical Centre, Soham
Joint Clinical Research Facility - Swansea, Swansea
Lead Sponsor
Novo Nordisk A/S
INDUSTRY